- Non-extending lenders no longer at risk of losing protections
- Terms of the deal have been sweetened; spread boosted
A leveraged loan deal from Amneal Pharmaceuticals LLC has been revamped after facing investor pushback.
JPMorgan Chase & Co., which is leading the proposed transaction, has boosted the spread on the loan and is knocking the price down to 95 cents on the dollar, according to people familiar with the matter. The minimum loan amount is now $2.25 billion, and commitments were due November 3 at 11:00 a.m. New York time, said the people who are not authorized to speak publicly.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.